Developer docs
API playgroundTry for free, no card

Search company profiles

CellCentric

Full company profile

uuid00008bq

Namestring
CellCentric
Legal namestring
CellCentric Limited
Websiteurl
cellcentric.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

CellCentric is a clinical-stage biotechnology company founded in 2003/2004 as a University of Cambridge spinout by Professor Azim Surani, headquartered in Cambridge, UK with additional operations in Manchester, UK and Burlington, MA (US office opened April 2025). The company is singularly focused on developing inobrodib (formerly CCS1477), a first-in-class oral small molecule inhibitor of p300/CBP bromodomains. Inobrodib binds selectively to the bromodomain of p300/CBP and displaces these transcription co-activators from super-enhancer sites, reducing expression of cancer-driving genes including MYC and IRF4, while leaving similar pockets on other proteins unaffected. The molecule has been evaluated in over 450 patients across multiple tumor types as monotherapy and in combination with standard-of-care agents.

The company's lead clinical focus is relapsed/refractory multiple myeloma (RRMM), with the all-oral InoPd regimen (inobrodib + pomalidomide + dexamethasone) positioned as the primary registration pathway. CellCentric has received FDA Fast Track and Orphan Drug designations for inobrodib in multiple myeloma and initiated the pivotal DOMMINO-1 Phase 2 trial in March 2026, with the global Phase 3 DOMMINO-2 trial planned for H2 2026. Secondary indications under investigation include metastatic castration-resistant prostate cancer, AML, lymphomas, and tumors with p300/CBP mutations.

CellCentric is pre-revenue with no commercial product sales. Its business model is a clinical-stage drug development approach, generating value through advancing inobrodib toward regulatory approval and eventual commercialization or partnership-driven monetization. Revenue mechanics are not yet established; pricing has not been disclosed. Go-to-market preparation is underway, evidenced by US office expansion and CEO statements regarding potential IPO timing with cash runway extending through 2029. The company has raised over $220 million in cumulative funding across multiple rounds, with the May 2026 $220M Series D (the largest private biotech financing in Europe for 2026) led by Venrock Healthcare Capital Partners.

Short descriptiontext

CellCentric is a clinical-stage biotechnology company developing inobrodib, a first-in-class oral p300/CBP bromodomain inhibitor, for treating relapsed/refractory multiple myeloma and other cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic cancer therapy, small molecule oncology, multiple myeloma treatment, p300/CBP inhibitor, clinical-stage biopharmaceutical
Industry3 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Commercialization
TypeOne Time License
Description

CellCentric is a clinical-stage biotech with no current revenue. The company plans to commercialize inobrodib for multiple myeloma and other cancer indications following successful clinical trials and regulatory approval. CEO Will West indicated an IPO is possible next year with cash runway extending through 2029.

fiercebiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CellCentric develops inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP bromodomains, for the treatment of multiple myeloma and other cancers. The drug binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes such as MYC and IRF4, and is being advanced through clinical trials as monotherapy and in combination with standard of care agents.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 69% objective response rate at 20mg dose in heavily pretreated RRMM patients
+2 more records
Product overview1 text field

CellCentric is a clinical-stage biopharmaceutical company developing a single core product, inobrodib (formerly known as CCS1477), an oral first-in-class small molecule p300/CBP inhibitor for treating multiple myeloma and other cancers. The company operates as a drug development company advancing this one lead therapeutic candidate through clinical trials, with a focus on relapsed/refractory multiple myeloma. Inobrodib is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone), with the all-oral combination regimen (InoPd) representing the primary development path toward registration.

Product and service1 record
1Inobrodib (CCS1477)
CategoryCore investigational drug product
Description

Inobrodib is a first-in-class oral small molecule inhibitor of p300/CBP bromodomains, developed for the treatment of multiple myeloma and other cancers. It binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes including MYC and IRF4. It is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-09-05
Description

Agreement to explore relevance of CCS1477 in treating haematological cancers. Prof. Pasqualucci originally identified p300/CBP as common target mutations in DLBCL and follicular lymphoma.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key clinical trial site for haematological malignancies program. Prof. Tim Somervaille serves as Chief Investigator of the Phase 1/2 haematological malignancy study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Initial clinical trial site for prostate cancer studies. Prof. Johann de Bono, Regius Professor of Cancer Research at ICR and Royal Marsden, serves as lead clinical Principal Investigator.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biotech developing chromatin remodeling / BRG1-BRM inhibitors and other epigenetic cancer therapies. Highly comparable to CellCentric as a small-cap, single-platform epigenetic drug developer with a similar capital and clinical development profile.

TypeDirect peer
Description

Commercial and clinical-stage company developing selinexor (XPO1 inhibitor) for relapsed/refractory multiple myeloma. Directly comparable as the most established late-line oral MM competitor with similar patient population and clinical positioning.

TypeDirect peer
Description

Clinical-stage small molecule oncology company developing targeted therapies including PRT3789 (SMARCA2 degrader) and other epigenetic targets. Similar profile as a clinical-stage, single-platform oncology biotech focused on chromatin biology.

TypeDirect peer
Description

Clinical-stage cancer therapeutics company developing epigenetic and immune-targeted therapies including revumenib (menin inhibitor) for AML. Comparable profile as a clinical-stage developer of mechanism-driven cancer therapies with FDA-approved product in recent launch.

TypeDirect peer
Description

Clinical-stage biotechnology company developing targeted protein degradation (PROTAC) therapies for cancer. Similar business profile as a clinical-stage single-platform oncology biotech with novel mechanism of action and similar capital intensity.

TypeDirect peer
Description

Clinical-stage oncology company developing molecular glue degraders for cancer and other diseases. Highly comparable as a clinical-stage single-platform biotech with novel mechanism of action targeting previously undruggable proteins.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Major multiple myeloma franchise holder with Revlimid, Pomalyst, and Empliciti, plus broad oncology portfolio. Comparable as the established leader in the MM treatment paradigm where CellCentric's inobrodib aims to compete in late-line settings.

TypeBroad incumbent
Description

Holds the dominant MM franchise with Darzalex (anti-CD38) and Carvykti (BCMA CAR-T). Directly relevant incumbent whose marketed and pipeline MM therapies define the standard of care against which inobrodib must differentiate.

TypeBroad incumbent
Description

CellCentric's strategic investor and SAB partner, also holder of Elrexfio (BCMA bispecific) and broader oncology portfolio. Comparable as a potential strategic acquirer and incumbent competitor in the MM space.

TypeBroad incumbent
Description

Holds Imdelltra (talquetamab) and other MM therapies including Blincyto franchise extension. Comparable broad incumbent with late-line MM therapies competing for the same patient population that inobrodib targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds20 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellCentric

Oncology Pharmaceuticalscellcentric.com

CellCentric is a clinical-stage biotechnology company developing inobrodib, a first-in-class oral p300/CBP bromodomain inhibitor, for treating relapsed/refractory multiple myeloma and other cancers.

What CellCentric does

CellCentric is a clinical-stage biotechnology company founded in 2003/2004 as a University of Cambridge spinout by Professor Azim Surani, headquartered in Cambridge, UK with additional operations in Manchester, UK and Burlington, MA (US office opened April 2025). The company is singularly focused on developing inobrodib (formerly CCS1477), a first-in-class oral small molecule inhibitor of p300/CBP bromodomains. Inobrodib binds selectively to the bromodomain of p300/CBP and displaces these transcription co-activators from super-enhancer sites, reducing expression of cancer-driving genes including MYC and IRF4, while leaving similar pockets on other proteins unaffected. The molecule has been evaluated in over 450 patients across multiple tumor types as monotherapy and in combination with standard-of-care agents.

The company's lead clinical focus is relapsed/refractory multiple myeloma (RRMM), with the all-oral InoPd regimen (inobrodib + pomalidomide + dexamethasone) positioned as the primary registration pathway. CellCentric has received FDA Fast Track and Orphan Drug designations for inobrodib in multiple myeloma and initiated the pivotal DOMMINO-1 Phase 2 trial in March 2026, with the global Phase 3 DOMMINO-2 trial planned for H2 2026. Secondary indications under investigation include metastatic castration-resistant prostate cancer, AML, lymphomas, and tumors with p300/CBP mutations.

CellCentric is pre-revenue with no commercial product sales. Its business model is a clinical-stage drug development approach, generating value through advancing inobrodib toward regulatory approval and eventual commercialization or partnership-driven monetization. Revenue mechanics are not yet established; pricing has not been disclosed. Go-to-market preparation is underway, evidenced by US office expansion and CEO statements regarding potential IPO timing with cash runway extending through 2029. The company has raised over $220 million in cumulative funding across multiple rounds, with the May 2026 $220M Series D (the largest private biotech financing in Europe for 2026) led by Venrock Healthcare Capital Partners.

CellCentric firmographics

Firmographics
Name
CellCentric
Legal name
CellCentric Limited
Website
https://cellcentric.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
CellCentric is a clinical-stage biotechnology company developing inobrodib, a first-in-class oral p300/CBP bromodomain inhibitor, for treating relapsed/refractory multiple myeloma and other cancers.
Ownership category
akta.pro rank

CellCentric industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Epigenetic cancer therapy
  • Small molecule oncology
  • Multiple myeloma treatment
  • P300/CBP inhibitor
  • Clinical-stage biopharmaceutical

Where CellCentric is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

CellCentric business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Commercialization: CellCentric is a clinical-stage biotech with no current revenue. The company plans to commercialize inobrodib for multiple myeloma and other cancer indications following successful clinical trials and regulatory approval. CEO Will West indicated an IPO is possible next year with cash runway extending through 2029.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

CellCentric product offering

Product offering

Core offering

CellCentric develops inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP bromodomains, for the treatment of multiple myeloma and other cancers. The drug binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes such as MYC and IRF4, and is being advanced through clinical trials as monotherapy and in combination with standard of care agents.

Product overview

CellCentric is a clinical-stage biopharmaceutical company developing a single core product, inobrodib (formerly known as CCS1477), an oral first-in-class small molecule p300/CBP inhibitor for treating multiple myeloma and other cancers. The company operates as a drug development company advancing this one lead therapeutic candidate through clinical trials, with a focus on relapsed/refractory multiple myeloma. Inobrodib is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone), with the all-oral combination regimen (InoPd) representing the primary development path toward registration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Inobrodib (CCS1477) Inobrodib is a first-in-class oral small molecule inhibitor of p300/CBP bromodomains, developed for the treatment of multiple myeloma and other cancers. It binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes including MYC and IRF4. It is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone).

Quantifiable outcome

  • 69% objective response rate at 20mg dose in heavily pretreated RRMM patients
  • +2 more outcomes

Companies that use CellCentric

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

CellCentric technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CellCentric partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Columbia University (Prof. Laura Pasqualucci)minorStrategic or Co-development Partner · 5 September 2017Agreement to explore relevance of CCS1477 in treating haematological cancers. Prof. Pasqualucci originally identified p300/CBP as common target mutations in DLBCL and follicular lymphoma.
  • The Christie NHS Foundation TrustcoreStrategic or Co-development PartnerKey clinical trial site for haematological malignancies program. Prof. Tim Somervaille serves as Chief Investigator of the Phase 1/2 haematological malignancy study.
  • Royal Marsden NHS Foundation TrustcoreStrategic or Co-development PartnerInitial clinical trial site for prostate cancer studies. Prof. Johann de Bono, Regius Professor of Cancer Research at ICR and Royal Marsden, serves as lead clinical Principal Investigator.

Scale indicators9 records

Recent moves1 record

Expansion highlights5 records

CellCentric competitors and assessment

Company assessment

Direct peers

  • Foghorn Therapeutics: Clinical-stage oncology biotech developing chromatin remodeling / BRG1-BRM inhibitors and other epigenetic cancer therapies. Highly comparable to CellCentric as a small-cap, single-platform epigenetic drug developer with a similar capital and clinical development profile.
  • Karyopharm Therapeutics: Commercial and clinical-stage company developing selinexor (XPO1 inhibitor) for relapsed/refractory multiple myeloma. Directly comparable as the most established late-line oral MM competitor with similar patient population and clinical positioning.
  • Prelude Therapeutics: Clinical-stage small molecule oncology company developing targeted therapies including PRT3789 (SMARCA2 degrader) and other epigenetic targets. Similar profile as a clinical-stage, single-platform oncology biotech focused on chromatin biology.
  • Syndax Pharmaceuticals: Clinical-stage cancer therapeutics company developing epigenetic and immune-targeted therapies including revumenib (menin inhibitor) for AML. Comparable profile as a clinical-stage developer of mechanism-driven cancer therapies with FDA-approved product in recent launch.
  • Arvinas: Clinical-stage biotechnology company developing targeted protein degradation (PROTAC) therapies for cancer. Similar business profile as a clinical-stage single-platform oncology biotech with novel mechanism of action and similar capital intensity.
  • Monte Rosa Therapeutics: Clinical-stage oncology company developing molecular glue degraders for cancer and other diseases. Highly comparable as a clinical-stage single-platform biotech with novel mechanism of action targeting previously undruggable proteins.

Broad incumbents

  • Bristol-Myers Squibb: Major multiple myeloma franchise holder with Revlimid, Pomalyst, and Empliciti, plus broad oncology portfolio. Comparable as the established leader in the MM treatment paradigm where CellCentric's inobrodib aims to compete in late-line settings.
  • Johnson & Johnson: Holds the dominant MM franchise with Darzalex (anti-CD38) and Carvykti (BCMA CAR-T). Directly relevant incumbent whose marketed and pipeline MM therapies define the standard of care against which inobrodib must differentiate.
  • Pfizer: CellCentric's strategic investor and SAB partner, also holder of Elrexfio (BCMA bispecific) and broader oncology portfolio. Comparable as a potential strategic acquirer and incumbent competitor in the MM space.
  • Amgen: Holds Imdelltra (talquetamab) and other MM therapies including Blincyto franchise extension. Comparable broad incumbent with late-line MM therapies competing for the same patient population that inobrodib targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CellCentric social profiles

Digital presence

CellCentric compliance and trust

Trust signal

Compliance2 records

CellCentric financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellCentric leadership team

Management profile

Number of profiles

Profiles19 records

CellCentric funding detail

Funding detail

Funding overview

Funding rounds20 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellCentric M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellCentric

What does CellCentric do?

CellCentric develops inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP bromodomains, for the treatment of multiple myeloma and other cancers. The drug binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes such as MYC and IRF4, and is being advanced through clinical trials as monotherapy and in combination with standard of care agents.

Is CellCentric a public or private company?

CellCentric is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellCentric founded?

CellCentric was founded in 2004. It employs 51 to 100 people.

Where is CellCentric based?

CellCentric is headquartered in Cambridge, United Kingdom, in the Europe region.

How does CellCentric make money?

One revenue line is on record: drug Commercialization.

Who are CellCentric's main competitors?

Direct peers on record are Foghorn Therapeutics, Karyopharm Therapeutics, Prelude Therapeutics, Syndax Pharmaceuticals, Arvinas and Monte Rosa Therapeutics. Broad incumbents are Bristol-Myers Squibb, Johnson & Johnson, Pfizer and Amgen.

Does CellCentric have an API?

No public API is recorded for CellCentric.

What industry is CellCentric in?

CellCentric's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate소피노바, 7억2500만 유로 바이오 투자펀드 조성…유럽 신약개발 기업 성장 지원 : 네이트 뉴스Sofinnova Partners raised €725 million for its second crossover fund, the largest of its series, to support European biotech firms. The fund will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and includes participation from the European Technology Champions Initiative.MarketScreenerSofinnova closes EUR725 million fund to back European biotech expansionSofinnova Partners closed a EUR725 million crossover fund, above its target, to back European biotechs seeking global competition. The fund, Crossover II, will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and aims to build companies for longevity without M&A.BioPharma DiveOne of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners raised €725M ($815M) for its second crossover fund, targeting companies near commercialization. The fund will invest in about 15 drugmakers and medical device developers, mostly in Europe. The firm's largest fund has already funded companies like CellCentric and Hemab Therapeutics.YahooOne of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners raised €725 million ($815 million) for its second crossover fund, targeting companies near commercialization. The fund will invest in about 15 drugmakers and medical device developers, mostly in Europe, and has already funded companies like CellCentric and Hemab Therapeutics.Targeted OncologyPivotal Trial Initiated for Inobrodib Combination in R/R Multiple MyelomaCellCentric has initiated the DOMMINO-1 pivotal phase 2 clinical trial for inobrodib combined with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. The study, which began treating patients at sites in the United Kingdom and the United States, aims to enroll 100 adults based on positive dose-optimization data showing a 69% overall response rate at the selected 20 mg dose.Labiotech.euThe Naming Patterns Behind 12,000 Biotech CompaniesAn analysis of over 12,000 biotech company names found that names beginning with A, C, or S are most common across categories, while Q, W, X, Y, and Z are least common. Exceptions exist in microbiome and psychedelics sectors, where M, E, P, S, and B dominate. The pattern likely stems from pre-internet directory preferences and broader naming trends.InvestorsinhealthcareUK: CellCentric raises US$220m in oversubscribed Series D financingCellCentric, a clinical-stage biotechnology company, completed an oversubscribed US$220m Series D financing led by Venrock Healthcare Capital Partners, with participation from Fidelity Management & Research Company, Sofinnova Partners and others. The company is developing a new drug for multiple sclerosis.Pulse 2.0CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple MyelomaCellCentric announced the completion of a $220 million Series D financing to support pivotal clinical trials of inobrodib, its first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma. The round was led by Venrock Healthcare Capital Partners with participation from Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare, and existing investors including RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge. Proceeds will fund continued enrollment in the Phase 2 DOMMINO-1 study in the UK and US and the planned initiation of a global Phase 3 DOMMINO-2 trial in H2 2026, along with expansion into additional combination and maintenance treatment settings.The Pharma LetterCellCentric closes $220 million Series D financingCellCentric closed an oversubscribed $220 million Series D financing. The funds will advance inobrodib through pivotal clinical studies, including continued enrollment in the Phase II DOMMINO-1 trial and initiation of the global Phase III DOMMINO-2 trial in the second half of 2026. Capital will also support expansion into additional combination and maintenance settings.BioSpaceCellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026Pfizer-backed biotech CellCentric has secured $220 million in a Series D funding round, making it the largest private biotech financing in Europe for 2026 thus far. The proceeds will fund a pivotal Phase 3 trial (DOMMINO-2) for inobrodib, the company's investigational first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma, with the trial expected to begin in the second half of 2026. The round was led by Venrock Healthcare Capital Partners with participation from Pfizer, Fidelity Management, Sofinnova Partners, RA Capital Management, and Forbion.